LPL Financial’s Monte Rosa Therapeutics GLUE Stock Holding History

LPL Financial’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,450	Closed	-$238K	–	6268
2026 Q1	$238K	Buy	+14,450	New	+$276K	﹤0.01%	5367

Other funds holding GLUE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LPL Financial's GLUE Position: Q2 2026 in Review

LPL Financial sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 14,450 shares — an estimated $238K sold.

LPL Financial first reported a position in GLUE in Q1 2026 and held it in 1 quarter. The position peaked at $238K in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

LPL Financial reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
LPL Financial sold 14,450 Monte Rosa Therapeutics shares in Q2 2026, an estimated $238K.
LPL Financial first reported a position in Monte Rosa Therapeutics in Q1 2026 and held it in 1 quarter.
LPL Financial's Monte Rosa Therapeutics position peaked at $238K in Q1 2026.
193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.